| Literature DB >> 30949508 |
Zi-Long Yao1,2, Qing-Rong Lin1, Yan-Jun Hu1, Yi-Long Hou1, Yun-Fei Ma1, Bin Yu1,2, Nan Jiang1,2.
Abstract
BACKGROUND: Previous studies had indicated that interleukin-1 beta (IL-1β) gene single nucleotide polymorphisms (SNPs) associate with different inflammatory diseases. However, potential links between these polymorphisms and susceptibility to extremity chronic osteomyelitis (COM) remain unclear. This study aimed to investigate relationships between IL-1β gene polymorphisms (rs16944, rs1143627, rs1143634, and rs2853550) and risks of developing extremity COM in Chinese Han population.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30949508 PMCID: PMC6425336 DOI: 10.1155/2019/7483537
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Forward, reverse, and extension primers of the 4 tag SNPs for PCR.
| SNPs | Forward and reverse primers (5′-3′) | Extension primers (5′-3′) |
|---|---|---|
| rs16944 | F: ATGTGGGACAAAGTGGAAGAC | TTTTTTTTTTTTCTTGGGTGCTGTTCTCTGCCTC |
| R: AATTTTCTCCTCAGAGGCTC | ||
| rs1143627 | F: CCACCAATACTCTTTTCCCC | TTTTTTTTTTTTTTTTTCCTACTTCTGCTTTTGAAAGC |
| R: CCTTAGCACCTAGTTGTAAG | ||
| rs1143634 | F: CTACTGGTGTTGTCATCAGAC | TTTTTTTTTTTTTTTTTTAAGCCTCGTTATCCCATGTGTC |
| R: AGCTTTTTTGCTGTGAGTCCC | ||
| rs2853550 | F: ACTAAAGCCCACTCCTCATTG | TTTTTTTTTTTTTTTTTTTTTCAGAAGGATATTCAGTGCACAT |
| R:ATAGCGCTTGCTCAACAGATG |
SNPs: single nucleotide polymorphisms.
PCR: polymerase chain reaction.
Comparisons of genotype distribution, allele frequency, and genetic models between COM patients and healthy controls.
| SNP ID | Items | Patients | Healthy controls |
| OR (95%CI) | |
|---|---|---|---|---|---|---|
| rs16944 | Genotype (n, %) | AA | 40 (17.17) | 52 (26.0) | 0.079 | NA |
| AG | 120 (51.50) | 90 (45.0) | ||||
| GG | 73 (31.33) | 58 (29.0) | ||||
| Allele | G vs. A | 266/200 | 206/194 | 0.100 | 1.253 (0.958-1.638) | |
| Dominant | GG+AG vs. AA | 193/40 | 148/52 |
| 1.698 (1.065-2.707) | |
| Recessive | GG vs. AA+AG | 73/160 | 58/142 | 0.586 | 1.122 (0.742-1.696) | |
| Homozygous | GG vs. AA | 73/40 | 58/52 | 0.071 | 1.643 (0.958-2.818) | |
| Heterozygous | AG vs. AA | 120/40 | 90/52 |
| 1.733 (1.055-2.847) | |
| rs1143627 | Genotype (n, %) | CC | 42 (18.03) | 51 (25.5) | 0.163 | NA |
| CT | 118 (50.64) | 94 (47.0) | ||||
| TT | 73 (31.33) | 55 (27.5) | ||||
| Allele | T vs. C | 264/202 | 204/196 | 0.096 | 1.256 (0.960-1.642) | |
| Dominant | TT+CT vs. CC | 191/42 | 149/51 | 0.061 | 1.557 (0.980-2.473) | |
| Recessive | TT vs. CC+CT | 73/160 | 55/145 | 0.368 | 1.211 (0.798-1.838) | |
| Homozygous | TT vs. CC | 73/42 | 55/51 | 0.080 | 1.620 (0.944-2.779) | |
| Heterozygous | CT vs. CC | 118/42 | 94/51 | 0.095 | 1.520 (0.930-2.485) | |
| rs1143634 | Genotype (n, %) | CC | 229 (98.28) | 194 (97.0) | 0.524 | NA |
| CT | 4 (1.72) | 6 (3.0) | ||||
| TT | 0 (0.0) | 0 (0.0) | ||||
| Allele | T vs. C | 4/462 | 6/394 | 0.574 | 0.569 (0.159-2.029) | |
| Dominant | TT+CT vs. CC | 4/229 | 6/194 | 0.402 | 0.577 (0.160-2.084) | |
| Recessive | TT vs. CC+CT | 0/233 | 0/200 | NA | NA | |
| Homozygous | TT vs. CC | 0/229 | 0/194 | NA | NA | |
| Heterozygous | CT vs. CC | 4/229 | 6/194 | 0.402 | 0.577 (0.160-2.084) | |
| rs2853550 | Genotype (n, %) | CC | 206 (88.41) | 171 (85.5) | 0.281 | NA |
| CT | 27 (11.59) | 27 (13.5) | ||||
| TT | 0 (0.0) | 2 (1.00) | ||||
| Allele | T vs. C | 27/439 | 31/369 | 0.251 | 0.732 (0.429-1.249) | |
| Dominant | TT+CT vs. CC | 27/206 | 29/171 | 0.315 | 0.749 (0.425-1.317) | |
| Recessive | TT vs. CC+CT | 0/233 | 2/198 | 0.999 | 0.000 (0.000- | |
| Homozygous | TT vs. CC | 0/206 | 2/171 | 0.999 | 0.000 (0.000- | |
| Heterozygous | CT vs. CC | 27/206 | 27/171 | 0.459 | 0.805 (0.454-1.429) |
SNP: single-nucleotide polymorphism; OR: odds ratio; CI: confidence interval. NA: not available.
Comparisons of clinical features among different genotypes of the IL-1β gene polymorphisms in COM patients.
| Items | rs16944 | rs1143627 | rs1143634 | rs2853550 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG |
| CC | CT | TT |
| CC | CT |
| CC | CT |
| |
| Age Median (IQR) | 42.50 (27.00, 50.00) | 37.50 (24.00, 52.00) | 39.00 (28.50, 48.50) | 0.696 | 42.00 (27.00, 50.00) | 37.50 (24.00, 52.25) | 39.00 (28.50, 48.50) | 0.838 | 39.00 (26.00, 50.00) | 48.50 (39.50, 59.75) | 0.182 | 39.00 (26.00, 50.25) | 38.00 (27.00, 49.00) | 0.769 |
| Sex ratio (M/F) | 28/12 | 100/20 | 57/16 | 0.185 | 30/12 | 98/20 | 57/16 | 0.263 | 182/47 | 3/1 | 1.000 | 163/43 | 22/5 | 0.776 |
| Positive rate of culture (%) (E/T) | 68.97 (20/29) | 65.17 (58/89) | 61.82 (34/55) | 0.803 | 67.74 (21/31) | 65.52 (57/87) | 61.82 (34/55) | 0.839 | 64.91 (111/171) | 50 (1/2) | 1.000 | 62.18 (97/156) | 88.24 (15/17) | 0.033 |
| Polymicrobial infection (%) (E/T) | 30.00 (6/20) | 18.97 (11/58) | 20.59 (7/34) | 0.597 | 28.57 (6/21) | 19.30 (11/57) | 20.59 (7/34) | 0.682 | 21.62 (24/111) | 0 (0/1) | 1.000 | 21.65 (21/97) | 20 (3/15) | 1.000 |
| WBC (×109/L) | 7.66 (6.33, 9.07) | 7.34 (5.59, 9.36) | 6.93 (6.11, 8.51) | 0.414 | 7.66 (6.38, 9.16) | 7.34 (5.55, 9.28) | 6.93 (6.11, 8.51) | 0.346 | 7.24 (5.94, 8.93) | 7.30 (5.46, 7.90) | 0.660 | 7.25 (6.03, 8.77) | 7.39 (5.41, 9.99) | 0.833 |
| CRP (mg/L) Median (IQR) | 3.99 (1.67, 33.36) | 6.20 (2.28, 21) | 7.65 (2.41, 18.58) | 0.646 | 3.99 (1.48, 29.61) | 6.20 (2.32, 21.20) | 7.65 (2.41, 18.58) | 0.567 | 6.25 (2.24, 19.70) | 6.51 (2.31, 14.18) | 0.844 | 6.57 (2.37, 19.35) | 4.67 (1.57, 17.56) | 0.459 |
| PCT (ng/ml) Median (IQR) | 0.037 (0.020, 0.053) | 0.035 (0.023, 0.069) | 0.038 (0.026, 0.051) | 0.894 | 0.038 (0.020, 0.053) | 0.035 (0.023, 0.070) | 0.038 (0.026, 0.051) | 0.912 | 0.037 (0.023, 0.062) | 0.030 (0.024, 0.038) | 0.499 | 0.037 (0.024, 0.062) | 0.027 (0.020, 0.051) | 0.273 |
| IL-6 (pg/ml) Median (IQR) | 7.98 (3.73, 18.17) | 21.10 (8.71, 74.49) | 12.44 (4.34, 53.46) |
| 7.98 (3.60, 20.08 | 21.1 (8.84, 74.50) | 12.44 (4.34, 53.46) |
| 15.39 (6.55, 59.78) | 24.29 (4.05, 38.95) | 0.781 | 14.76 (6.22, 59.35) | 24.67 (8.10, 77.43) | 0.379 |
| TNF- | 9.67 (7.67, 11.20) | 9.78 (7.56, 13.05) | 8.73 (7.21, 11.53) | 0.494 | 9.7 (8.04, 11.60) | 9.42 (7.55, 13.10) | 8.73 (7.21, 11.53) | 0.510 | 9.26 (7.38, 12.00) | 9.04 (8.07, 12.77) | 0.872 | 9.16 (7.50, 12.00) | 10.40 (6.65, 13.50) | 0.698 |
| SAA (mg/L) Median (IQR) | 7.40 (2.45, 28.25) | 9.40 (4.20, 37.40) | 5.00 (3.23, 61.75) | 0.776 | 8.15 (2.48, 26.58) | 8.55 (4.18, 37.53) | 5.00 (3.23, 61.75) | 0.861 | 7.60 (3.30, 29.05) | 272.30 | 0.135 | 8.30 (3.33, 30.33) | 5.25 (2.85, 222.05) | 0.858 |
COM: chronic osteomyelitis; IQR: interquartile range; M/F: male/female; E/T: events/total; WBC: white blood cell count; CRP: C-reactive protein; PCT: procalcitonin; IL-6: interleukin-6; TNF-a: tumor necrosis factor-a; SAA: serum amyloid A.
Figure 1(a) Comparisons regarding preoperative serum IL-6 level among different genotypes of rs16944 in COM patients. (b) Comparisons regarding preoperative serum IL-6 level between AA+GG and AG groups in COM patients (red dotted line: median; blue error bars: IQR).
Figure 2(a) Comparisons regarding preoperative serum IL-6 level among different genotypes of rs1143627 in COM patients. (b) Comparisons regarding preoperative serum IL-6 level between CC and CT+TT groups in COM patients (red dotted line: median; blue error bars: IQR).